{
    "organizations": [],
    "uuid": "36f5eec6192d97058872713b264c791fd06ee85a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-xiangxue-pharmaceutical-sees-fy-20/brief-xiangxue-pharmaceutical-sees-fy-2018-q1-net-profit-could-rise-up-to-20-pct-idUSL4N1RF20R",
    "ord_in_thread": 0,
    "title": "BRIEF-Xiangxue Pharmaceutical sees FY 2018 Q1 net profit could rise up to 20 pct",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 2 (Reuters) - Xiangxue Pharmaceutical Co Ltd\n* Says it sees FY 2018 Q1 net profit to increase by up to 20 percent, or to be 22.5 million yuan to 27 million yuan\n* Says FY 2017 Q1 net profit was 22.5 million yuan\n* Comments that increased sales of antiviral oral-liquid as main reason for the forecast\nSource text in Chinese: goo.gl/HKMo6J\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-04-02T12:34:00.000+03:00",
    "crawled": "2018-04-03T16:05:33.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "xiangxue",
        "pharmaceutical",
        "co",
        "ltd",
        "say",
        "see",
        "fy",
        "q1",
        "net",
        "profit",
        "increase",
        "percent",
        "million",
        "yuan",
        "million",
        "yuan",
        "say",
        "fy",
        "q1",
        "net",
        "profit",
        "million",
        "yuan",
        "comment",
        "increased",
        "sale",
        "antiviral",
        "main",
        "reason",
        "forecast",
        "source",
        "text",
        "chinese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}